Patents by Inventor Tetsuya Nakatsura
Tetsuya Nakatsura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240018224Abstract: An object of the present invention is to provide: an anti-GPC3 antibody that recognizes an epitope different from that for existing antibodies (e.g., GC33 and GC199) and can specifically bind, even in the form of single chain antibody, to GPC3 localized on a cell membrane; CAR comprising the anti-GPC3 single chain antibody; an immunocompetent cell expressing the CAR; a gene of the anti-GPC3 antibody or a gene of the CAR; a vector comprising the anti-GPC3 antibody gene or the CAR gene; a host cell in which the vector has been introduced; a method for specifically detecting GPC3; and a kit for specifically detecting GPC3. An antibody comprising particular heavy chain CDR1 to CDR3 and particular light chain CDR1 to CDR3 defined in claim 1, and specifically binding to a human-derived GPC3 polypeptide specifically binds to GPC3 localized on a cell membrane. CAR-immunocompetent cells prepared on the basis of CAR comprising such single chain antibody are useful for cancer immunotherapy.Type: ApplicationFiled: June 15, 2023Publication date: January 18, 2024Applicants: Yamaguchi University, National Cancer Center, Noile-Immune Biotech, Inc.Inventors: Koji TAMADA, Yukimi SAKODA, Tetsuya NAKATSURA, Keigo SAITO
-
Publication number: 20240021281Abstract: An information management apparatus includes at least one processor configured to acquire first time information and second time information, the first time information being related to a time taken to acquire a predetermined amount of at least one or more specific nucleic acids based on a first cell acquired from a cancer patient, the second time information being related to a time taken to culture a second cell different from the first cell until a predetermined amount is reached; and store individual patient information in which the first time information and the second time information are associated with attribute information of the cancer patient.Type: ApplicationFiled: September 27, 2023Publication date: January 18, 2024Inventors: Masahiro OKANOJO, Tatsuya MATSUNO, Mao KAMEDA, Yushi SATO, Shangwu CHEN, Yuma SUZUKI, Ryosuke TAKAHASHI, Tetsuya NAKATSURA
-
Publication number: 20240016935Abstract: A genetically modified cell includes (i) an exogenous oligomeric polypeptide having a variable region and a constant region, and (ii) exogenous CD8 ?-chain and ?-chain polypeptides.Type: ApplicationFiled: September 27, 2023Publication date: January 18, 2024Inventors: Tatsuya MATSUNO, Masahiro OKANOJO, Ryosuke TAKAHASHI, Tetsuya NAKATSURA, Toshihiro SUZUKI
-
Publication number: 20230257708Abstract: Provided is a T cell receptor containing, as ? chain complementarity determining regions, respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 1 to 3, or respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 4 to 6, as ? chain complementarity determining regions, respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 7 to 9, or respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 10 to 12, and capable of binding to a peptide having the amino acid sequence shown in SEQ ID NO: 27 or a complex of the peptide and HLA-A24.Type: ApplicationFiled: February 6, 2023Publication date: August 17, 2023Inventors: Tetsuya Nakatsura, Toshiaki Yoshikawa, Yasushi Uemura, Kyoko Fukuda, Shin Kaneko, Atsutaka Minagawa, Yoshiaki Kassai, Atsushi Matsuda
-
Patent number: 11718663Abstract: An object of the present invention is to provide: an anti-GPC3 antibody that recognizes an epitope different from that for existing antibodies (e.g., GC33 and GC199) and can specifically bind, even in the form of single chain antibody, to GPC3 localized on a cell membrane; CAR comprising the anti-GPC3 single chain antibody; an immunocompetent cell expressing the CAR; a gene of the anti-GPC3 antibody or a gene of the CAR; a vector comprising the anti-GPC3 antibody gene or the CAR gene; a host cell in which the vector has been introduced; a method for specifically detecting GPC3; and a kit for specifically detecting GPC3. An antibody comprising particular heavy chain CDR1 to CDR3 and particular light chain CDR1 to CDR3 defined in claim 1, and specifically binding to a human-derived GPC3 polypeptide specifically binds to GPC3 localized on a cell membrane. CAR-immunocompetent cells prepared on the basis of CAR comprising such single chain antibody are useful for cancer immunotherapy.Type: GrantFiled: January 10, 2018Date of Patent: August 8, 2023Assignees: Yamaguchi University, National Cancer Center, Noile-Immune Biotech, Inc.Inventors: Koji Tamada, Yukimi Sakoda, Tetsuya Nakatsura, Keigo Saito
-
Patent number: 11603519Abstract: Provided is a T cell receptor capable of binding to a peptide having the amino acid sequence shown in SEQ ID NO: 27 or a complex of the peptide and HLA-A24. A T cell receptor capable of binding to a peptide having the amino acid sequence shown in SEQ ID NO: 28 or a complex of the peptide and HLA-A02. Disclosed T cell receptors are useful in treating or avoiding cancers which are associated with expression of glypican-3.Type: GrantFiled: February 5, 2018Date of Patent: March 14, 2023Assignees: National Cancer Center Japan, Kyoto University, Takeda Pharmaceutical Company LimitedInventors: Tetsuya Nakatsura, Toshiaki Yoshikawa, Yasushi Uemura, Kyoko Fukuda, Shin Kaneko, Atsutaka Minagawa, Yoshiaki Kassai, Atsushi Matsuda
-
Patent number: 10781249Abstract: An object of the present invention is to provide: an anti-GPC3 antibody that recognizes an epitope different from that for existing antibodies (e.g., GC33 and GC199) and can specifically bind, even in the form of single chain antibody, to GPC3 localized on a cell membrane; CAR comprising the anti-GPC3 single chain antibody; an immunocompetent cell expressing the CAR; a gene of the anti-GPC3 antibody or a gene of the CAR; a vector comprising the anti-GPC3 antibody gene or the CAR gene; a host cell in which the vector has been introduced; a method for specifically detecting GPC3; and a kit for specifically detecting GPC3. An antibody comprising particular heavy chain CDR1 to CDR3 and particular light chain CDR1 to CDR3 defined in claim 1, and specifically binding to a human-derived GPC3 polypeptide specifically binds to GPC3 localized on a cell membrane. CAR-immunocompetent cells prepared on the basis of CAR comprising such single chain antibody are useful for cancer immunotherapy.Type: GrantFiled: August 21, 2019Date of Patent: September 22, 2020Assignees: Yamaguchi University, National Cancer Center, Noile-Immune Biotech, Inc.Inventors: Koji Tamada, Yukimi Sakoda, Tetsuya Nakatsura, Keigo Saito
-
Patent number: 10730935Abstract: An object of the present invention is to provide: an anti-GPC3 antibody that recognizes an epitope different from that for existing antibodies (e.g., GC33 and GC199) and can specifically bind, even in the form of single chain antibody, to GPC3 localized on a cell membrane; CAR comprising the anti-GPC3 single chain antibody; an immunocompetent cell expressing the CAR; a gene of the anti-GPC3 antibody or a gene of the CAR; a vector comprising the anti-GPC3 antibody gene or the CAR gene; a host cell in which the vector has been introduced; a method for specifically detecting GPC3; and a kit for specifically detecting GPC3. An antibody comprising particular heavy chain CDR1 to CDR3 and particular light chain CDR1 to CDR3 defined in claim 1, and specifically binding to a human-derived GPC3 polypeptide specifically binds to GPC3 localized on a cell membrane. CAR-immunocompetent cells prepared on the basis of CAR comprising such single chain antibody are useful for cancer immunotherapy.Type: GrantFiled: August 21, 2019Date of Patent: August 4, 2020Assignees: Yamaguchi University, National Cancer Center, Noile-Immune Biotech, Inc.Inventors: Koji Tamada, Yukimi Sakoda, Tetsuya Nakatsura, Keigo Saito
-
Publication number: 20200010804Abstract: Provided is a T cell receptor containing, as ? chain complementarity determining regions, respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 1 to 3, or respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 4 to 6, as ? chain complementarity determining regions, respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 7 to 9, or respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 10 to 12, and capable of binding to a peptide having the amino acid sequence shown in SEQ ID NO: 27 or a complex of the peptide and HLA-A24.Type: ApplicationFiled: February 5, 2018Publication date: January 9, 2020Inventors: Tetsuya Nakatsura, Toshiaki Yoshikawa, Yasushi Uemura, Kyoko Fukuda, Shin Kaneko, Atsutaka Minagawa, Yoshiaki Kassai, Atsushi Matsuda
-
Publication number: 20190367634Abstract: An object of the present invention is to provide: an anti-GPC3 antibody that recognizes an epitope different from that for existing antibodies (e.g., GC33 and GC199) and can specifically bind, even in the form of single chain antibody, to GPC3 localized on a cell membrane; CAR comprising the anti-GPC3 single chain antibody; an immunocompetent cell expressing the CAR; a gene of the anti-GPC3 antibody or a gene of the CAR; a vector comprising the anti-GPC3 antibody gene or the CAR gene; a host cell in which the vector has been introduced; a method for specifically detecting GPC3; and a kit for specifically detecting GPC3. An antibody comprising particular heavy chain CDR1 to CDR3 and particular light chain CDR1 to CDR3 defined in claim 1, and specifically binding to a human-derived GPC3 polypeptide specifically binds to GPC3 localized on a cell membrane. CAR-immunocompetent cells prepared on the basis of CAR comprising such single chain antibody are useful for cancer immunotherapy.Type: ApplicationFiled: August 21, 2019Publication date: December 5, 2019Applicants: YAMAGUCHI UNIVERSITY, NATIONAL CANCER CENTER, NOILE-IMMUNE BIOTECH, INC.Inventors: KOJI TAMADA, YUKIMI SAKODA, TETSUYA NAKATSURA, KEIGO SAITO
-
Publication number: 20190359698Abstract: An object of the present invention is to provide: an anti-GPC3 antibody that recognizes an epitope different from that for existing antibodies (e.g., GC33 and GC199) and can specifically bind, even in the form of single chain antibody, to GPC3 localized on a cell membrane; CAR comprising the anti-GPC3 single chain antibody; an immunocompetent cell expressing the CAR; a gene of the anti-GPC3 antibody or a gene of the CAR; a vector comprising the anti-GPC3 antibody gene or the CAR gene; a host cell in which the vector has been introduced; a method for specifically detecting GPC3; and a kit for specifically detecting GPC3. An antibody comprising particular heavy chain CDR1 to CDR3 and particular light chain CDR1 to CDR3 defined in claim 1, and specifically binding to a human-derived GPC3 polypeptide specifically binds to GPC3 localized on a cell membrane. CAR-immunocompetent cells prepared on the basis of CAR comprising such single chain antibody are useful for cancer immunotherapy.Type: ApplicationFiled: January 10, 2018Publication date: November 28, 2019Applicants: Yamaguchi University, National Cancer Center, Noile-Immune Biotech, Inc.Inventors: Koji TAMADA, Yukimi SAKODA, Tetsuya NAKATSURA, Keigo SAITO
-
Publication number: 20190350979Abstract: An undifferentiated stem cell removal agent is provided, containing at least one component selected from the group consisting of the following (a) to (d): (a) a cell that is capable of specifically inhibiting proliferation of a glypican-3-expressing cell; (b) a compound that is capable of specifically inhibiting proliferation of a glypican-3-expressing cell; (c) a cell that is capable of inducing a specific immune response against a glypican-3-expressing cell; and (d) a compound that is capable of inducing a specific immune response against a glypican-3-expressing cell.Type: ApplicationFiled: December 14, 2017Publication date: November 21, 2019Inventors: Keiichi FUKUDA, Tetsuya NAKATSURA
-
Publication number: 20190066846Abstract: The present invention relates to a method for assisting recurrence risk prediction for hepatocellular carcinoma patients. The method comprises measuring glypican 3 (GPC3) peptide recognized by both a first monoclonal antibody and a second monoclonal antibody in a blood sample of a hepatocellular carcinoma patient, by contacting the sample with the first monoclonal antibody that recognizes a peptide having an amino acid sequence in the N-terminal side of GPC3 and the second monoclonal antibody that recognizes a peptide having an amino acid sequence in the C-terminal side of GPC3, and detecting the complex comprising GPC3 peptide, the first antibody and the second antibody.Type: ApplicationFiled: September 7, 2018Publication date: February 28, 2019Applicants: SYSMEX CORPORATION, NATIONAL CANCER CENTERInventors: Tetsuya NAKATSURA, Keigo SAITO, Masahiro MIURA, Kozo SUTO, Takuya IINO
-
Publication number: 20170049870Abstract: The present application relates to an antigen peptide derived from the sequence of epidermal growth factor receptor having T790M point mutation and a pharmaceutical composition for the treatment of cancer comprising the peptide.Type: ApplicationFiled: October 21, 2016Publication date: February 23, 2017Applicant: Kanagawa Prefectural Hospital OrganizationInventors: Tetsuro Sasada, Tetsuya Nakatsura, Kazuya Ofuji
-
Patent number: 9505824Abstract: The present application relates to an antigen peptide derived from the sequence of epidermal growth factor receptor having T790M point mutation and a pharmaceutical composition for the treatment of cancer comprising the peptide.Type: GrantFiled: August 8, 2013Date of Patent: November 29, 2016Assignee: Kanagawa Prefectural Hospital OrganizationInventors: Tetsuro Sasada, Tetsuya Nakatsura, Kazuya Ofuji
-
Patent number: 9465030Abstract: Provided is a kit for diagnosing at a high reproducibility, said kit being produced by preparing a monoclonal antibody against GPC3 and a monoclonal antibody against SPARC that are superior in quality stability to commercially available and commonly employed antibodies, and using these antibodies.Type: GrantFiled: June 17, 2013Date of Patent: October 11, 2016Assignees: NATIONAL CANCER CENTER, LSIP, LLCInventors: Tetsuya Nakatsura, Keigo Saito
-
Patent number: 9404925Abstract: An object of the present invention to provide: a human pancreatic cancer antigen and/or a human colon cancer antigen that can be applied to the diagnosis and/or treatment of various types of cancers or tumors including pancreatic cancer and colon cancer as representative examples; a gene encoding the same; an anti-cancer vaccine using the same; or the like. The present invention provides a cancer antigen comprising a protein having the amino acid sequence shown in SEQ ID NO: 1; a peptide comprising a portion of said protein and having immune-stimulating activity; an anti-cancer vaccine comprising said peptide; a DNA having the nucleotide sequence shown in SEQ ID NO: 2, or its complementary sequence or a part or full length of these sequence; an anti-cancer vaccine comprising said DNA; and use thereof.Type: GrantFiled: June 11, 2008Date of Patent: August 2, 2016Assignee: MEDINET CO., LTD.Inventors: Tetsuya Nakatsura, Yasuharu Nishimura
-
Publication number: 20150218248Abstract: The present application relates to an antigen peptide derived from the sequence of epidermal growth factor receptor having T790M point mutation and a pharmaceutical composition for the treatment of cancer comprising the peptide.Type: ApplicationFiled: August 8, 2013Publication date: August 6, 2015Applicant: Kanagawa Prefectural Hospital OrganizationInventors: Tetsuro Sasada, Tetsuya Nakatsura, Kazuya Ofuji
-
Publication number: 20150198598Abstract: Provided is a kit for diagnosing at a high reproducibility, said kit being produced by preparing a monoclonal antibody against GPC3 and a monoclonal antibody against SPARC that are superior in quality stability to commercially available and commonly employed antibodies, and using these antibodies.Type: ApplicationFiled: June 17, 2013Publication date: July 16, 2015Applicants: LSIP, LLC, NATIONAL CANCER CENTERInventors: Tetsuya Nakatsura, Keigo Saito
-
Patent number: 8535942Abstract: It is an object of the present invention to identify a glypican-3-derived peptide which can bind to HLA-A2 and activate human killer T cells, so as to provide a means for carrying out an immunotherapy which is able to target approximately 40% of Japanese patients suffering from several types of cancers, which express GPC3 at a high level. The present invention provides a peptide of any of the following (A) or (B): (A) a peptide, which has the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3; or (B) a peptide, which has an amino acid sequence comprising a substitution or addition of one or two amino acids with respect to the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3, and which has ability to induce killer T cells.Type: GrantFiled: September 23, 2011Date of Patent: September 17, 2013Assignee: Oncotherapy Science, Inc.Inventors: Yasuharu Nishimura, Tetsuya Nakatsura, Hiroyuki Komori